Rankings
▼
Calendar
AKBA (Akebia Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
AKBA
Akebia Therapeutics, Inc.
Mkt Cap
$365M
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$236M
Net Income (TTM)
-$5M
EPS (TTM)
-$0.02
Free Cash Flow (TTM)
$68M
Gross Margin
83.3%
Op. Margin
9.9%
Net Margin
-2.3%
FCF Margin
28.6%
P/S Ratio (TTM)
1.5x
P/E Ratio (TTM)
—
YoY Rev Growth
+47.5%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$40M
$20M
-$26M
Q2 23
$56M
$39M
-$9M
Q3 23
$42M
$24M
-$13M
Q4 23
$56M
$38M
$1M
Q1 24
$33M
$30M
-$15M
Q2 24
$44M
$35M
-$9M
Q3 24
$37M
$23M
-$13M
Q4 24
$46M
$26M
-$14M
Q1 25
$57M
$50M
$14M
Q2 25
$62M
$53M
$14M
Q3 25
$59M
$49M
$4M
Q4 25
$58M
$45M
-$9M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
1.4x
—
Q2 23
1.8x
—
Q3 23
1.9x
—
Q4 23
1.9x
—
Q1 24
2.0x
—
Q2 24
2.1x
—
Q3 24
2.1x
—
Q4 24
2.3x
—
Q1 25
2.0x
—
Q2 25
1.8x
—
Q3 25
1.6x
—
Q4 25
1.5x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$18M
-$18M
Q2 23
$4M
$4M
Q3 23
-$7M
-$7M
Q4 23
-$2M
-$2M
Q1 24
-$19M
-$19M
Q2 24
-$10M
-$10M
Q3 24
-$7M
-$7M
Q4 24
-$4M
-$4M
Q1 25
-$14M
-$14M
Q2 25
$22M
$22M
Q3 25
$28M
$28M
Q4 25
$31M
$31M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$0
Q2 23
$0
Q3 23
$0
Q4 23
$0
Q1 24
$0
Q2 24
$29K
Q3 24
$2K
Q4 24
$2K
Q1 25
$18K
Q2 25
$126K
Q3 25
$77K
Q4 25
$162K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-35.2%
-45.4%
Q2 23
-55.4%
-29.2%
Q3 23
-13.7%
-44.4%
Q4 23
+1.8%
-10.9%
Q1 24
-18.5%
-27.5%
Q2 24
-22.6%
-19.9%
Q3 24
-11.0%
-9.3%
Q4 24
-17.3%
+10.9%
Q1 25
+75.8%
-7.8%
Q2 25
+43.1%
-7.6%
Q3 25
+57.0%
+8.8%
Q4 25
+23.9%
+8.8%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$2M
6.2%
Q2 23
$3M
6.2%
Q3 23
$2M
4.3%
Q4 23
$2M
2.7%
Q1 24
$2M
7.2%
Q2 24
$2M
4.7%
Q3 24
$2M
4.4%
Q4 24
$0
0.0%
Q1 25
$2M
3.8%
Q2 25
$3M
4.3%
Q3 25
$3M
5.5%
Q4 25
$3M
5.6%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$20M
—
$25M
—
Q2 23
$20M
—
$27M
—
Q3 23
$13M
—
$23M
—
Q4 23
$10M
—
$25M
—
Q1 24
$10M
—
—
—
Q2 24
$8M
—
—
—
Q3 24
$8M
—
—
$27M
Q4 24
$12M
$23M
$5M
—
Q1 25
$10M
—
—
$26M
Q2 25
$11M
—
—
$27M
Q3 25
$15M
—
—
$30M
Q4 25
$27M
—
—
$26M
marketcaparena.com
Revenue Segments
License Collaboration And Other Revenue
Product
Quarter
License Collaboration And Other Revenue
Product
Q1 23
$5M
$35M
Q2 23
$14M
$42M
Q3 23
$2M
$40M
Q1 24
$2M
$31M
Q2 24
$2M
$41M
Q3 24
$2M
$36M
Q1 25
$2M
$56M
Q2 25
$2M
$60M
Q3 25
$2M
$57M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$57M
$0
$57M
Q2 23
$54M
$0
$54M
Q3 23
$47M
$0
$47M
Q4 23
$43M
$0
$43M
Q1 24
$42M
$0
$42M
Q2 24
$39M
$0
$39M
Q3 24
$34M
$0
$34M
Q4 24
$52M
$0
$52M
Q1 25
$113M
$0
$113M
Q2 25
$137M
$0
$137M
Q3 25
$166M
$0
$166M
Q4 25
$185M
$0
$185M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
185M
+0.4%
Q2 23
187M
+1.1%
Q3 23
188M
+0.8%
Q4 23
190M
+1.2%
Q1 24
205M
+7.6%
Q2 24
210M
+2.3%
Q3 24
210M
+0.3%
Q4 24
219M
+4.0%
Q1 25
242M
+10.5%
Q2 25
271M
+12.2%
Q3 25
274M
+1.2%
Q4 25
265M
-3.3%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$0
43
FY 15
$0
64
FY 16
$17K
90
FY 17
$2M
114
FY 18
$639K
325
FY 19
$931K
360
FY 20
$775K
380
FY 21
$497K
426
FY 22
$1M
205
FY 23
$1M
167
FY 24
$885K
181
FY 25
$6K
40K
marketcaparena.com